BioAge Labs (BIOA) EBITDA (2023 - 2026)

BioAge Labs has disclosed EBITDA across 4 years of filings, most recently posting -$29.3 million for Q2 2026.

• In Q2 2026, EBITDA fell 18.42% year-over-year to -$29.3 million; the TTM figure through Jun 2026 stood at -$106.3 million (down 16.36% YoY), while the FY2025 annual figure was -$92.8 million, down 18.65% from the prior year.
• EBITDA came in at -$29.3 million for Q2 2026 at BioAge Labs, down from -$25.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.9 million in Q3 2023 to a low of -$29.3 million in Q2 2026.
• Average EBITDA over 4 years is -$20.8 million, with a median of -$23.9 million recorded in 2024.
• Year-over-year, EBITDA slumped 150.33% in 2024 and grew 6.51% in 2025.
• Over 4 years, EBITDA stood at -$13.6 million in 2023, then slumped by 86.54% to -$25.4 million in 2024, then declined by 12.07% to -$28.4 million in 2025, then dropped by 3.2% to -$29.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$29.3 million in Q2 2026, -$25.4 million in Q1 2026, and -$28.4 million in Q4 2025.